Menu

TS Picks: March 16, 2016

Corrections give belated credit for immunotherapy; mosquitoes have been bugging us long before Zika; the bright side of irreproducibility 

Mar 16, 2016
Kerry Grens

WIKIPEDIA, CAROL A. JACOBSON AND JEROME RITZ

Selections from The Scientist’s reading list:
 

  • The New England Journal of Medicine is correcting three papers from a team led by the University of Pennsylvania’s Carl June, who is credited with pioneering a cancer immunotherapy. As MIT Technology Review reported this week (March 14), the publications did not appropriately credit the scientists who designed the chimeric antigen receptor critical for the treatment. “It’s been beneficial for immunotherapy,” Dario Campana, one of the now-acknowledged scientists, told Tech Review. “But we developed this receptor. There is no question about that.”  
     
  • As the Zika virus advances through the Americas, The Washington Post this week (March 14) offered a grim reminder that the pathogen is just the latest malady humans have suffered at the hands—er, bites—of mosquitoes. For a century we have known that the insects can carry deadly diseases, but efforts to destroy their populations have failed, and there’s evidence now that some mosquitoes have become resistant to a pesticide. “We thought we had taken care of the Aedes mosquito,” entomologist Janet McAllister of the US Centers for Disease Control and Prevention told the Washington Post. “Now, the problem has come back to haunt us.”
     
  • Psychology has gone through a shake-up recently after studies suggested considerable, albeit debated, reproducibility problems. Yet an article in Vox this week (March 14) looked on the bright side: “If psychology finds it has to start from scratch evaluating its hypotheses, at least it will be able to do so in a manner that’s more methodologically sound.” Quartz had a similar take: “The idea that papers are publishing false results might sound alarming but the recent crisis doesn’t mean that the entire scientific method is totally wrong. In fact, science’s focus on its own errors is a sign that researchers are on exactly the right path.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.